专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005028480A3 5-ARYL-PYRAZOLO[4,3-D]PYRIMIDINES, PYRIDINES, AND PYRAZINES AND RELATED COMPOUNDS 审中-公开
标题翻译： 5-亚氨基 - 吡唑并[4,3-D]吡啶，吡啶和吡啶及相关化合物
公开(公告)号：WO2005028480A3
公开(公告)日：2005-06-02
申请号：PCT/US2004028663
申请日：2004-09-03
申请人： NEUROGEN CORP , AVENTIS PHARMA INC , HODGETTS KEVIN J , JOHN STANLY , MOORCROFT NEIL , SHUTSKE GREG , KAISER BERND , YAMAGUCHI YASUCHIKA , GE PING , HORVATH RAYMOND F
发明人： HODGETTS KEVIN J , JOHN STANLY , MOORCROFT NEIL , SHUTSKE GREG , KAISER BERND , YAMAGUCHI YASUCHIKA , GE PING , HORVATH RAYMOND F
IPC分类号： A61K31/519 , A61K31/53 , C07D471/04 , C07D487/02 , C07D487/04 , C07D519/00 , A61K31/437 , A61P25/18 , A61P25/22
CPC分类号： C07D487/04 , C07D471/04 , C07D519/00
摘要： 5-aryl-Pyrazolo[4,3-d] pyrimidines, 6-aryl-Pyrazolo[3,4-d]pyrimidines and related compounds, as well as other chemically related compounds, that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRIF receptor binding. Methods of using the compounds in receptor localization studies are given.
摘要翻译：提供了作为CRF 1受体的选择性调节剂的5-芳基 - 吡唑并[4,3-d]嘧啶，6-芳基 - 吡唑并[3,4-d]嘧啶和相关化合物以及其它化学相关化合物。这些化合物可用于治疗许多中枢神经系统和周围疾病，特别是压力，焦虑，抑郁，心血管疾病和进食障碍。还提供了治疗这种疾病以及包装的药物组合物的方法。本发明的化合物也可用作CRF受体定位的探针，并且作为用于CRIF受体结合的测定中的标准物。给出了在受体定位研究中使用化合物的方法。

2. 发明申请

WO1996013503A1 CERTAIN TRICYCLIC SUBSTITUTED DIAZABICYCLO[3.2.1] OCTANE DERIVATIVES 审中-公开
标题翻译：某些三取代的DIAZABICYCLO [3.2.1] OCTANE DERIVATIVES
公开(公告)号：WO1996013503A1
公开(公告)日：1996-05-09
申请号：PCT/US1994012566
申请日：1994-11-01
申请人： NEUROGEN CORPORATION , HUTCHISON, Alan , YUAN, Jun , HORVATH, Raymond, F.
发明人： NEUROGEN CORPORATION
IPC分类号： C07D487/08
CPC分类号： C07D487/08
摘要： This invention encompasses compounds of formula (I), where either R1 or R2 represents (II) and the other represents hydrogen or straight or branched chain lower alkyl having 1-6 carbon atoms; and X is oxygen, methylene, or NH; Y represents various inorganic and organic substituents; Z is hydrogen, amino or NHR6 where R6 is lower alkyl having 1-6 carbon atoms; T is hydrogen, halogen, hydroxy, or lower alkoxy having 1-6 carbon atoms; and A is methylene, carbonyl or CHOH. These compounds are selective partial agonists or antagonists at brain monoamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Furthermore compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents. These compounds show unexpectedly atypical antipsychotic profiles (clozapine-like) in the animal models described in this patent.
摘要翻译：本发明包括式（I）的化合物，其中R 1或R 2表示（II），另一个表示氢或具有1-6个碳原子的直链或支链低级烷基; X为氧，亚甲基或NH; Y表示各种无机和有机取代基; Z是氢，氨基或NHR6，其中R6是具有1-6个碳原子的低级烷基; T是氢，卤素，羟基或具有1-6个碳原子的低级烷氧基; A是亚甲基，羰基或CHOH。这些化合物是脑单胺受体亚型或其前药的选择性部分激动剂或拮抗剂，并且可用于诊断和治疗情感障碍如精神分裂症和抑郁症以及某些运动障碍如帕金森综合征。此外，本发明的化合物可用于治疗与使用常规精神抑制剂相关的锥体束外副作用。这些化合物在本专利描述的动物模型中显示出意想不到的非典型抗精神病药谱（氯氮平样）。

3. 发明申请

WO2007133756A2 CRF1 RECEPTOR LIGANDS COMPRISING HETEROARYL FUSED BICYCLES 审中-公开
标题翻译： CRF1受体配体包含HETEROARYL FUSED BICYCLES
公开(公告)号：WO2007133756A2
公开(公告)日：2007-11-22
申请号：PCT/US2007011588
申请日：2007-05-15
申请人： NEUROGEN CORP , HORVATH RAYMOND F , ZHANG LU YAN
发明人： HORVATH RAYMOND F , ZHANG LU YAN
IPC分类号： A61M29/00
CPC分类号： C07D487/04 , C07D471/04 , C07D519/00
摘要： Substituted heteroaryl fused pyridine and pyrazine compounds that act as selective modulators of CRFl receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, gastrointestinal disorders, and eating disorders. Methods of treatment of such disorders as well as packaged pharmaceutical compositions are also provided. Compounds provided herein are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.
摘要翻译：提供了作为CRF1受体的选择性调节剂的取代的杂芳基稠合的吡啶和吡嗪化合物。这些化合物可用于治疗许多中枢神经系统和周围疾病，特别是压力，焦虑，抑郁，心血管疾病，胃肠道疾病和进食障碍。还提供了治疗这些疾病以及包装的药物组合物的方法。本文提供的化合物也可用作CRF受体定位的探针，并且作为用于CRF受体结合的测定中的标准物。给出了在受体定位研究中使用化合物的方法。

4. 发明申请

WO0160806A3 SUBSTITUTED ARYLPYRAZINES 审中-公开
标题翻译：取代的芳基
公开(公告)号：WO0160806A3
公开(公告)日：2002-02-07
申请号：PCT/US0105264
申请日：2001-02-16
申请人： NEUROGEN CORP , YOON TAEYOUNG , GE PING , HORVATH RAYMOND F , LOMBAERT STEPHANE DE , HODGETTS KEVIN J , DOLLER DARIO , ZHANG CUNYU
发明人： YOON TAEYOUNG , GE PING , HORVATH RAYMOND F , DE LOMBAERT STEPHANE , HODGETTS KEVIN J , DOLLER DARIO , ZHANG CUNYU
IPC分类号： A61K31/4965 , A61K31/5377 , A61P1/00 , A61P1/04 , A61P9/10 , A61P9/12 , A61P15/00 , A61P19/10 , A61P25/00 , A61P25/18 , A61P25/22 , A61P25/24 , A61P43/00 , C07D241/00 , C07D241/12 , C07D241/18 , C07D241/20 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/12 , C07D409/04 , C07D241/52
CPC分类号： C07D401/04 , A61K31/496 , A61K31/4965 , A61K31/497 , A61K31/5355 , C07D241/12 , C07D241/18 , C07D241/20 , C07D401/12 , C07D403/04 , C07D405/12 , C07D409/04
摘要： Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affiity and high selectivity to CRF1 receptors, including human CRF1 receptors. The invention thus includes methods for treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.
摘要翻译：提供了芳基吡嗪化合物，包括可以以高亲和力和对CRF1受体（包括人类CRF1受体）的高选择性结合的芳基吡嗪。因此，本发明包括用于治疗与CRF1受体相关的疾病和疾病的方法，所述疾病和疾病包括CNS相关疾病和疾病，特别是情感障碍和疾病，以及急性和慢性神经障碍和疾病。

5. 发明申请

WO2005115399A3 IMIDAZOPYRAZINES, IMIDAZOPYRIDINES, ANS IMIDAZOPYRIMIDINES AS CRF1 RECEPTOR LIGANDS 审中-公开
标题翻译：作为CRF1受体配体的咪唑吡嗪，咪唑嗪，ANS咪唑吡啶
公开(公告)号：WO2005115399A3
公开(公告)日：2006-03-16
申请号：PCT/US2005013049
申请日：2005-04-15
申请人： NEUROGEN CORP , DOLLER DARIO , ZHANG LU YAN , GE PING , YAMAGUCHI YASUCHIKA , HORVATH RAYMOND F , ZHANG XUECHUN
发明人： DOLLER DARIO , ZHANG LU YAN , GE PING , YAMAGUCHI YASUCHIKA , HORVATH RAYMOND F , ZHANG XUECHUN
IPC分类号： A61K31/498 , A61K31/519 , C07D471/04 , C07D487/04 , A01N43/04 , A01N43/42 , A01N43/58 , A01N43/60 , A61K31/44 , A61K31/495 , A61K31/50 , A61K31/53 , C07D471/00 , C07D487/00 , C07D491/00
CPC分类号： C07D487/04 , C07D471/04
摘要： Novel aryl substituted imidazopyrazines, imidazopyrimidines, and imidazopyridines are provided. Such compounds can act as selective modulators of CRF receptors. The 5-substituted-2-arylpyridine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.
摘要翻译：提供了新的芳基取代的咪唑并吡嗪，咪唑并嘧啶和咪唑并吡啶。这些化合物可以作为CRF受体的选择性调节剂。本文提供的5-取代-2-芳基吡啶化合物可用于治疗许多CNS和周围疾病，特别是压力，焦虑，抑郁，心血管疾病和进食障碍。还提供了治疗这种疾病以及包装的药物组合物的方法。提供的化合物也可用作CRF受体定位的探针，并且作为用于CRF受体结合的测定中的标准物。给出了在受体定位研究中使用化合物的方法。

6. 发明申请

WO2005028480A2 5-ARYL-PYRAZOLO[4,3-D]PYRIMIDINES, PYRIDINES, AND PYRAZINES AND RELATED COMPOUNDS 审中-公开
标题翻译： 5-芳基吡唑并[4,3-D]嘧啶，吡啶和吡嗪及相关化合物
公开(公告)号：WO2005028480A2
公开(公告)日：2005-03-31
申请号：PCT/US2004/028663
申请日：2004-09-03
申请人： NEUROGEN CORPORATION , AVENTIS PHARMACEUTICALS INC. , HODGETTS, Kevin, J. , JOHN, Stanly , MOORCROFT, Neil , SHUTSKE, Greg , KAISER, Bernd , YAMAGUCHI, Yasuchika , GE, Ping , HORVATH, Raymond, F.
发明人： HODGETTS, Kevin, J. , JOHN, Stanly , MOORCROFT, Neil , SHUTSKE, Greg , KAISER, Bernd , YAMAGUCHI, Yasuchika , GE, Ping , HORVATH, Raymond, F.
IPC分类号： C07D487/00
CPC分类号： C07D487/04 , C07D471/04 , C07D519/00
摘要： 5-aryl-Pyrazolo[4,3- d ] pyrimidines, 6-aryl-Pyrazolo[3,4- d ]pyrimidines and related compounds, as well as other chemically related compounds, that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRIF receptor binding. Methods of using the compounds in receptor localization studies are given.
摘要翻译： 5-芳基 - 吡唑并[4,3-d]嘧啶，6-芳基 - 吡唑并[3,4-d 提供了充当CRF1受体的选择性调节剂的嘧啶和相关化合物以及其他化学相关化合物。这些化合物可用于治疗许多CNS和周围疾病，特别是压力，焦虑，抑郁，心血管疾病和进食障碍。还提供了治疗此类病症的方法以及包装的药物组合物。本发明化合物还可用作CRF受体定位探针，并作为CRIF受体结合测定的标准。给出了在受体定位研究中使用这些化合物的方法。

7. 发明申请

WO0123389A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES 审中-公开
标题翻译：某些亚烷基二胺取代的杂环
公开(公告)号：WO0123389A2
公开(公告)日：2001-04-05
申请号：PCT/US0026886
申请日：2000-09-29
申请人： NEUROGEN CORP , PFIZER , HORVATH RAYMOND F , TRAN JENNIFER , LOMBAERT STEPHANE DE , HODGETTS KEVIN JULIAN , CARPINO PHILIP A , GRIFFITH DAVID A
发明人： HORVATH RAYMOND F , TRAN JENNIFER , DE LOMBAERT STEPHANE , HODGETTS KEVIN JULIAN , CARPINO PHILIP A , GRIFFITH DAVID A
IPC分类号： A61K31/437 , A61K31/4375 , A61K31/4409 , A61K31/4706 , A61K31/505 , A61K31/519 , A61K31/522 , A61P1/12 , A61P3/04 , A61P3/06 , A61P3/10 , A61P5/06 , A61P5/48 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P11/02 , A61P11/06 , A61P13/12 , A61P15/00 , A61P15/10 , A61P25/00 , A61P25/04 , A61P25/06 , A61P25/08 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P29/00 , A61P43/00 , C07D213/73 , C07D213/74 , C07D215/46 , C07D239/48 , C07D471/04 , C07D471/14 , C07D473/34 , C07D475/06 , C07D475/08 , C07D487/04 , C07D495/04 , A61K31/4365 , A61K31/44 , A61K31/47 , G01N33/566
CPC分类号： C07D213/73 , C07D215/46 , C07D239/48 , C07D471/04 , C07D471/14 , C07D473/34 , C07D475/08 , C07D487/04 , C07D495/04 , G01N2333/5755 , G01N2333/70571
摘要： The present invention also provides a general method to whereby mono-, bi-, or tri-cyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. The present invention provides novel, potent, non-peptidic antagonists of NPY receptors, particularly, the NPY1 receptors, designed from a selection of mono-, bi-, or tri-cyclic heterocyclic cores. This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. The novel compounds encompassed by the present invention are those of formula (I)-(XV), wherein X is N or CR ; W is S, O, or NR ; Y is N or CR ; E, F, and G are each, independently, CR or N; I and J are each, independently, C=O, S, O, CR R or NR when single bonded to both adjacent ring atoms, or N, or CR when double bonded to an adjacent ring atom; K is N or CR when double bonded to L or J, or O, S, C=O, CR R , or NR when single bonded to both adjacent ring atoms, or N or CR when double bonded to an adjacent ring atom; L is N or CR when single bonded to all atoms to which it is attached, or C (carbon) when double bonded to K; the 6- or 7-membered ring that contains I, J, K, and L may contain from 1 to 3 double bonds, from 0 to 2 heteroatoms, and from 0 to 2 C=O groups, wherein the carbon atom of such groups are part of the ring and the oxygen atom is a substituent on the ring; Q is O or NR . Such compounds inhibit the activity of neuropeptide Y at those receptors are useful in treating physiological disorders associated with an excess of neuropeptide Y, including eating disorders, such as, for example, obesity and bulimia, and certain cardiovascular diseases, for example, hypertension.
摘要翻译：本发明还提供一种通用方法，由此可以修饰单环，双环或三环杂环以在NPY1受体上获得有效的拮抗剂。本发明提供由选择的单，双或三环杂环核心设计的NPY受体特别是NPY1受体的新型有效的非肽拮抗剂。本发明涉及用于治疗与过量神经肽Y相关的生理障碍的新化合物，组合物和方法。本发明包括的新化合物是式（I） - （XV）的新化合物，其中X是N或 CR <14>; W是S，O或NR 15; Y是N或CR 3; E，F和G各自独立地为CR 3或N; 当单键结合到两个相邻的环原子上时，I和J各自独立地为C = O，S，O，CR 3 R 16或NR 15，当双键键合到相邻环原子; 当双键连接到两个相邻的环原子上时，K是N或CR 3，当双键连接到L或J或O，S，C = O，CR 3 R 16或NR 15时，或N 或CR 3，当与相邻的环原子双键时; 当单键与其所连接的所有原子单键键合时，L为N或CR 16，或当双键键合至K时为C（碳）; 含有I，J，K和L的6-或7-元环可以含有1至3个双键，0至2个杂原子和0至2个C = O基团，其中这些基团的碳原子是环的一部分，氧原子是环上的取代基; Q是O或NR 15。这些化合物抑制神经肽Y在这些受体上的活性可用于治疗与过量神经肽Y相关的生理紊乱，包括进食障碍，例如肥胖症和贪食症，以及某些心血管疾病，例如高血压。

8. 发明申请

WO1994025461A1 CERTAIN CYCLOALKYL AND AZACYCLOALKYL PYRROLOPYRIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS 审中-公开
标题翻译：某些环己基和亚乙基二烷基吡咯啉; 新类型的GABA脑受体配体
公开(公告)号：WO1994025461A1
公开(公告)日：1994-11-10
申请号：PCT/US1993003919
申请日：1993-04-30
申请人： NEUROGEN CORPORATION , BLUM, Charles, A. , HUTCHISON, Alan, J. , HORVATH, Raymond, F.
发明人： NEUROGEN CORPORATION
IPC分类号： C07D471/04
CPC分类号： C07D471/04 , C07D471/14
摘要： The present invention encompasses compounds of formula (I) and pharmaceutically acceptable non-toxic salts thereof wherein: A represents nitrogen or C-H, and B represents nitrogen or C-H, with the proviso that when A is nitrogen, B is C-H, and when B is nitrogen, A is C-H; n is 0, 1, or 2; Y represents nitrogen or carbon, each of which is substituted with various organic or inorganic substituents; W represents an aromatic group unsubstituted or substituted with various organic or inorganic substituents; and R1 and R2 are the same or different and represent hydrogen or lower alkyl. These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs thereof and are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overdose with benzodiazepine type drugs, and enhancement of alertness.
摘要翻译：本发明包括式（I）化合物及其药学上可接受的无毒盐，其中：A表示氮或CH，B表示氮或CH，条件是当A为氮时，B为CH，当B为氮，A是CH; n为0,1或2; Y表示氮或碳，各自被各种有机或无机取代基取代; W表示未被取代或被各种有机或无机取代基取代的芳基; R 1和R 2相同或不同，表示氢或低级烷基。这些化合物是用于GABAa脑受体或其前药的高度选择性激动剂，拮抗剂或反向激动剂，并且可用于诊断和治疗焦虑，睡眠和癫痫发作，用苯二氮卓类药物过量并提高警觉性。

9. 发明申请

WO1998045295A1 CERTAIN PYRROLOPYRIDINE DERIVATIVES; NOVEL CRF1 SPECIFIC LIGANDS 审中-公开
标题翻译：某些吡咯啉衍生物; 新型CRF1特殊配置
公开(公告)号：WO1998045295A1
公开(公告)日：1998-10-15
申请号：PCT/US1997005979
申请日：1997-04-10
申请人： NEUROGEN CORPORATION , HORVATH, Raymond, F. , HUTCHINSON, Alan
发明人： NEUROGEN CORPORATION
IPC分类号： C07D471/04
CPC分类号： C07D471/04 , C07D471/14
摘要： Disclosed are compounds of formula (I) wherein Ar is optionally substituted aryl or heteroaryl; R1 is hydrogen or alkyl; R7 is hydrogen or alkyl; R2 is hydrogen, halogen, alkyl or alkoxy; or R1 and R2 taken together with the ring to which they are attached for a 5-9 membered saturated or aromatic ring optionally having a hetero atom selected from oxygen, sulfur or nitrogen; R3 and R4 are independently hydrogen, alkyl, cycloalkyl, aryl or heteroaryl groups; or R3 and R4 together with the nitrogen atom to which they are attached form a 5-8 membered ring; and R5 is hydrogen, halogen, straight or branched chain lower alkyl having 1-6 carbon atoms, or straight or branched chain lower alkoxy or thioalkoxy having 1-6 carbon atoms, which compounds are highly selective partial agonists or antagonists at human Corticotropin-Releasing Factor 1 (CRF1) receptors and are useful in the diagnosis and treatment of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety.
摘要翻译：公开了式（I）的化合物，其中Ar是任选取代的芳基或杂芳基; R1是氢或烷基; R7是氢或烷基; R2是氢，卤素，烷基或烷氧基; 或R 1和R 2与它们所连接的环一起连接5-9元饱和或芳环，任选具有选自氧，硫或氮的杂原子; R3和R4独立地是氢，烷基，环烷基，芳基或杂芳基; 或R 3和R 4与它们所连接的氮原子一起形成5-8元环; R5为氢，卤素，具有1-6个碳原子的直链或支链低级烷基，或具有1-6个碳原子的直链或支链低级烷氧基或硫代烷氧基，该化合物是人促皮素激素释放的高度选择性部分激动剂或拮抗剂因子1（CRF1）受体，可用于治疗压力相关疾病如创伤后应激障碍（PTSD）以及抑郁，头痛和焦虑症的诊断和治疗。

10. 发明申请

WO1996016040A1 CERTAIN 4-AMINOMETHYL-2-SUBSTITUTED IMIDAZOLE DERIVATIVES AND 2-AMINOMETHYL-4-SUBSTITUTED IMIDAZOLE DERIVATIVES; NEW CLASSES OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS 审中-公开
标题翻译：某些4-氨基乙基-2-取代的咪唑衍生物和2-氨基乙基-4-取代的咪唑衍生物; 多巴胺受体亚型特异性配体的新类别
公开(公告)号：WO1996016040A1
公开(公告)日：1996-05-30
申请号：PCT/US1995015262
申请日：1995-11-22
申请人： NEUROGEN CORPORATION , THURKAUF, Andrew , HORVATH, Raymond, F. , YUAN, Jun , PETERSON, John, M.
发明人： NEUROGEN CORPORATION
IPC分类号： C07D233/54
CPC分类号： C07D233/64 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12
摘要： Disclosed are compounds of formula (III), wherein R1 represents optionally substituted aryl, heteroaryl, arylalkyl, or cycloalkyl groups; X, Z, and Y are optionally substituted nitrogen or carbon atoms; R3 and R4 are organic or inorganic substituents which may together form ring structures; m is zero, one or two; and R5 and R6 are organic or inorganic substituents; and the pharmaceutically acceptable addition salts thereof, which compounds are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism.
摘要翻译：公开了式（III）的化合物，其中R 1表示任选取代的芳基，杂芳基，芳基烷基或环烷基; X，Z和Y任选被取代的氮或碳原子; R3和R4是可以一起形成环结构的有机或无机取代基; m为零，一或二; R5和R6是有机或无机取代基; 和其药学上可接受的加成盐，该化合物是脑多巴胺受体亚型或其前药的高选择性部分激动剂或拮抗剂，并且可用于诊断和治疗情感障碍如精神分裂症和抑郁症以及某些运动障碍如帕金森综合征。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式